文献速递银屑病与炎症性皮肤病

银屑病患者发起式诊疗咨询的前瞻性52周随机对照试验

A prospective 52-week randomized controlled trial of patient-initiated care consultations for patients with psoriasis.
PubMed 文献 · Br J Dermatol · 2018-05-23

这项前瞻性随机对照试验纳入150例系统治疗控制良好的银屑病患者,随机分为患者发起式诊疗咨询组(每年1次皮肤科医生面诊,可按需发起咨询)与常规诊疗组(每12-16周面诊1次)。52周时两组皮肤病生活质量指数(DLQI)与银屑病面积和严重程度指数(PASI)均无统计学显著差异,患者发起式诊疗咨询组皮肤科咨询次数减少63%,治疗依从性与安全性两组相当,且该组就诊依从性显著更优。

要点

  • 52周时两组DLQI平均差0.28(95%CI -0.35至0.9),PASI平均差-0.24(95%CI -0.84至0.36),均无统计学显著差异。
  • 患者发起式诊疗咨询组皮肤科咨询次数较常规诊疗组减少63%:平均2.5±0.1次 vs 5.1±0.6次(P=0.001)。
  • 两组患者治疗依从性与安全性相当,患者发起式诊疗咨询组就诊依从性显著优于对照组(P=0.003)。

核心结论

  • 患者发起式诊疗咨询较常规诊疗提供额外临床获益,使患者对临床就诊的依赖减少。
  • 该干预未对系统治疗监测增加危害,患者报告生活质量高且对医疗保健满意。

研究设计与样本

  • 前瞻性随机对照试验,纳入150例系统治疗控制良好的银屑病患者,随机分为患者发起式诊疗咨询组与常规诊疗组。
  • 患者发起式诊疗咨询组每年参加1次皮肤科医生面诊,并可在需要时发起咨询;常规诊疗组每12-16周参加1次面诊。
  • 主要结局为皮肤病生活质量指数(DLQI),其他结局包括安全性、患者依从性及医疗保健满意度,于基线和52周后评估;试验注册号NCT02382081。

主要发现

  • 150例患者中58.0%使用生物制剂,37.3%使用甲氨蝶呤,4.7%使用阿维A。
  • 52周时两组DLQI平均差为0.28(95%CI -0.35至0.9),PASI平均差为-0.24(95%CI -0.84至0.36),均无统计学显著差异。
  • 患者发起式诊疗咨询组皮肤科咨询次数较常规诊疗组减少63%:平均2.5±0.1次 vs 5.1±0.6次(P=0.001)。
  • 两组治疗依从性与安全性相当,但患者发起式诊疗咨询组就诊依从性显著优于对照组(P=0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment and care of moderate-to-severe psoriasis require lifelong consultations with a dermatologist with close monitoring of systemic treatment. OBJECTIVES: To investigate the effect of patient-initiated care consultation (PICC) for patients with psoriasis in a dermatology outpatient clinic. METHODS: A prospective randomized controlled trial with patients on well-controlled systemic treatment randomized to either (i) the PICC group, where they participated in one annual consultation with a dermatologist but were able to initiate consultations when needed; or (ii) routine care, where they participated in a consultation every 12-16 weeks. The primary outcome was the Dermatology Life Quality Index (DLQI). Other outcomes were safety, patient adherence and satisfaction with healthcare assessed at baseline and after 52 weeks. The study was registered with clinical trials number NCT02382081. RESULTS: In total 150 patients were included, with 58·0% treated with biologics, 37·3% with methotrexate and 4·7% with acitretin. At week 52 no statistically significant mean difference between groups was detected in DLQI (0·28, 95% confidence interval -0·35 to 0·9) or Psoriasis Area and Severity Index (-0·24, 95% confidence interval -0·84 to 0·36). Patients in the PICC group requested 63% fewer consultations with a dermatologist: mean 2·5 ± 0·1 vs. 5·1 ± 0·6 (P = 0·001). Patient adherence and safety with treatment monitoring were equal between groups, but the PICC group was significantly better at attending consultations than the control group (P = 0·003). CONCLUSIONS: PICC offers additional clinical benefits over routine care, making patients less dependent on clinical visits. The intervention adds no harm to monitoring systemic treatment, and patients report high quality of life and satisfaction with healthcare.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Khoury LR, Møller T, Zachariae C, et al. A prospective 52-week randomized controlled trial of patient-initiated care consultations for patients with psoriasis. Br J Dermatol. 2018. PMID: 29363093. doi:10.1111/bjd.16369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。